trending Market Intelligence /marketintelligence/en/news-insights/trending/gUTGpy00G9t9rnzZ-01o1w2 content esgSubNav
In This List

Allergan tumor drug under scrutiny; Lilly arthritis treatment gets FDA nod

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Allergan tumor drug under scrutiny; Lilly arthritis treatment gets FDA nod

Top news

* The European Medicines Agency launched a review of Allergan plc's uterus tumor drug Esmya after four patients suffered serious liver injuries.

* The U.S. Food and Drug Administration approved Eli Lilly and Co.'s Taltz injection to treat adults with active psoriatic arthritis.

M&A and capital markets

* Novartis AG CEO Joseph Jimenez said the company is considering selling its oral solids business in the U.S. due to the worsening market for generic pills in the country, FiercePharma reported, citing comments at an analyst event.

* Vanc Pharmaceuticals Inc. entered into an agreement to acquire all outstanding common shares of Healthtab, Inc. for a total consideration of C$200,000.

* Neurosearch A/S is looking to either sell or liquidate the company as part of its action plan. The company's remaining assets include cash and cash equivalents of about 75 million Danish kroner, a small shareholding in Atonomics A/S, potential milestone payments from Teva Pharmaceutical Industries Ltd. and a tax loss of about 1.6 billion kroner.

* China SXT Pharmaceuticals Inc. filed for an IPO of up to $15 million to list on the Nasdaq capital market.

* Quanterix Corp. also filed for an IPO to sell 3,340,000 common shares at an estimated price of between $14 and $16 per share. The company plans to list on the Nasdaq global market under the QTRX symbol.

* resTORbio Inc. said it confidentially submitted a draft registration statement for an IPO of its common stock with the U.S. Securities and Exchange Commission.

Drug and product pipeline

* The Philippines Food and Drug Administration directed Sanofi to withdraw its dengue vaccine Dengvaxia from the market and suspend its sale, distribution and marketing pending regulatory compliance. The country previously launched a probe into the immunization of over 730,000 children who received the vaccine.

The World Health Organization said it supports the Philippine Department of Health's decision to suspend the vaccinations and that it plans to conduct a review by year-end, Reuters reported.

Meanwhile, EMA's Committee for Medicinal Products for Human Use is reviewing Dengvaxia for a central marketing authorization, Reuters reported, citing an emailed statement by the agency.

Further, the French pharmaceutical company said the risk of getting severe dengue in previously uninfected people who were given Dengvaxia was about two in 1,000, Reuters reported, citing an emailed statement from the company.

* Separately, Sanofi's discontinued Zika vaccine showed promising results in a phase 1 trial, Reuters reported, citing data published in The Lancet.

Operational activity

* Montana Attorney General Tim Fox filed a lawsuit against Purdue Pharma LP, accusing the company of deceptive marketing practice involving its prescription opioids, including OxyContin. Fox also accused the company of manipulating doctors, lying to consumers and making actions that contributed to thousands of deaths across the country.

Other features

* The Wall Street Journal writes about how researchers are exploring the capabilities of mobile devices as a way to monitor patients in medical trials.

* The Journal also has a feature on the potential for CRISPR gene editing tools to help fight antibiotic resistance.

The day ahead

Early morning futures indicators pointed to a mixed opening for the U.S. market.

In Asia, the Hang Seng dropped 1.01% to 28,842.80, while the Nikkei 225 slid 0.37% to 22,622.38.

In Europe, around midday, the FTSE 100 gained 0.16% to 7,350.74 and the Euronext 100 fell 0.39% to 1,038.59.

The Daily Dose is updated as of 6:30 a.m. ET. Some external links may require a subscription.